Lixte Biotechnology Holdings Inc (LIXT) - Net Assets
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) has net assets worth $10.96 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.73 Million) and total liabilities ($1.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LIXT tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.96 Million |
| % of Total Assets | 86.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | 128.83% |
| 10-Year Change | 5004.09% |
| Growth Volatility | 494.64 |
Lixte Biotechnology Holdings Inc - Net Assets Trend (2005–2025)
This chart illustrates how Lixte Biotechnology Holdings Inc's net assets have evolved over time, based on quarterly financial data. See Lixte Biotechnology Holdings Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Lixte Biotechnology Holdings Inc (2005–2025)
The table below shows the annual net assets of Lixte Biotechnology Holdings Inc from 2005 to 2025. For live valuation and market cap data, see how much is Lixte Biotechnology Holdings Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.96 Million | +1225.11% |
| 2024-12-31 | $827.22K | -79.29% |
| 2023-12-31 | $3.99 Million | -22.66% |
| 2022-12-31 | $5.17 Million | +7.83% |
| 2021-12-31 | $4.79 Million | -4.42% |
| 2020-12-31 | $5.01 Million | +105.90% |
| 2019-12-31 | $2.43 Million | -41.00% |
| 2018-12-31 | $4.13 Million | +314.64% |
| 2017-12-31 | $995.04K | +363.33% |
| 2016-12-31 | $214.76K | -31.24% |
| 2015-12-31 | $312.33K | +17.48% |
| 2014-12-31 | $265.86K | +12.53% |
| 2013-12-31 | $236.27K | -84.16% |
| 2012-12-31 | $1.49 Million | +1787.93% |
| 2011-12-31 | $79.02K | -95.45% |
| 2010-12-31 | $1.74 Million | +33.45% |
| 2009-12-31 | $1.30 Million | +502.13% |
| 2008-12-31 | $-323.55K | -185.84% |
| 2007-12-31 | $376.93K | -39.84% |
| 2006-12-31 | $626.56K | +8062.43% |
| 2005-12-31 | $-7.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lixte Biotechnology Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5804434400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $879.00 | 0.01% |
| Other Components | $67.74 Million | 700.95% |
| Total Equity | $9.66 Million | 100.00% |
Lixte Biotechnology Holdings Inc Competitors by Market Cap
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JKG Land Bhd
KLSE:6769
|
$59.97 Million |
|
Vince Holding Corp. Common Stock
NASDAQ:VNCE
|
$60.00 Million |
|
Safety Shot Inc
NASDAQ:SHOT
|
$60.00 Million |
|
Quantum X Labs Inc.
NASDAQ:QXL
|
$60.01 Million |
|
LLORENTE + CUENCA EO -01
F:91P
|
$59.94 Million |
|
Pansar Bhd
KLSE:8419
|
$59.93 Million |
|
Ikena Oncology Inc
NASDAQ:IKNA
|
$59.90 Million |
|
TEAM INC. DL-30
F:T9CA
|
$59.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lixte Biotechnology Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 827,219 to 9,664,059, a change of 8,836,840 (1068.3%).
- Net loss of 6,009,520 reduced equity.
- Dividend payments of 69,073,000 reduced retained earnings.
- New share issuances of 10,265,199 increased equity.
- Other factors increased equity by 73,654,161.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.01 Million | -62.18% |
| Dividends Paid | $69.07 Million | -714.74% |
| Share Issuances | $10.27 Million | +106.22% |
| Other Changes | $73.65 Million | +762.15% |
| Total Change | $- | 1068.26% |
Book Value vs Market Value Analysis
This analysis compares Lixte Biotechnology Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.00 | $6.96 | x |
| 2006-12-31 | $0.00 | $6.96 | x |
| 2007-12-31 | $0.00 | $6.96 | x |
| 2008-12-31 | $0.00 | $6.96 | x |
| 2009-12-31 | $0.00 | $6.96 | x |
| 2010-12-31 | $0.00 | $6.96 | x |
| 2011-12-31 | $0.00 | $6.96 | x |
| 2012-12-31 | $2.30 | $6.96 | x |
| 2013-12-31 | $0.34 | $6.96 | x |
| 2014-12-31 | $0.36 | $6.96 | x |
| 2015-12-31 | $0.40 | $6.96 | x |
| 2016-12-31 | $0.27 | $6.96 | x |
| 2017-12-31 | $1.07 | $6.96 | x |
| 2018-12-31 | $4.21 | $6.96 | x |
| 2019-12-31 | $2.18 | $6.96 | x |
| 2020-12-31 | $4.44 | $6.96 | x |
| 2021-12-31 | $3.56 | $6.96 | x |
| 2022-12-31 | $32.65 | $6.96 | x |
| 2023-12-31 | $2.09 | $6.96 | x |
| 2024-12-31 | $0.37 | $6.96 | x |
| 2025-12-31 | $0.20 | $6.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lixte Biotechnology Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-62.18%) is above the historical average (-386.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.08K |
| 2006 | -77.90% | 0.00% | 0.00x | 1.20x | $-550.74K |
| 2007 | -437.22% | 0.00% | 0.00x | 1.67x | $-1.69 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.24 Million |
| 2009 | -119.23% | 0.00% | 0.00x | 1.23x | $-1.68 Million |
| 2010 | -50.70% | 0.00% | 0.00x | 1.11x | $-1.05 Million |
| 2011 | -2617.03% | 0.00% | 0.00x | 5.44x | $-2.08 Million |
| 2012 | -0.24% | 0.00% | 0.00x | 1.18x | $-152.77K |
| 2013 | -581.97% | 0.00% | 0.00x | 2.36x | $-1.40 Million |
| 2014 | -1040.39% | 0.00% | 0.00x | 2.03x | $-2.79 Million |
| 2015 | -913.13% | -1426.00% | 0.33x | 1.91x | $-2.88 Million |
| 2016 | -994.01% | 0.00% | 0.00x | 2.02x | $-2.16 Million |
| 2017 | -181.74% | 0.00% | 0.00x | 1.37x | $-1.91 Million |
| 2018 | -51.70% | 0.00% | 0.00x | 1.05x | $-2.55 Million |
| 2019 | -98.21% | 0.00% | 0.00x | 1.10x | $-2.63 Million |
| 2020 | -65.14% | 0.00% | 0.00x | 1.04x | $-3.77 Million |
| 2021 | -140.46% | 0.00% | 0.00x | 1.06x | $-7.21 Million |
| 2022 | -122.21% | 0.00% | 0.00x | 1.08x | $-6.83 Million |
| 2023 | -127.34% | 0.00% | 0.00x | 1.08x | $-5.49 Million |
| 2024 | -433.50% | 0.00% | 0.00x | 1.38x | $-3.67 Million |
| 2025 | -62.18% | 0.00% | 0.00x | 1.32x | $-6.98 Million |
Industry Comparison
This section compares Lixte Biotechnology Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc (LIXT) | $10.96 Million | 0.00% | 0.16x | $59.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-… Read more